ES2055314T3 - Tratamiento de disfuncion leucocitaria con gm-csf. - Google Patents

Tratamiento de disfuncion leucocitaria con gm-csf.

Info

Publication number
ES2055314T3
ES2055314T3 ES90300840T ES90300840T ES2055314T3 ES 2055314 T3 ES2055314 T3 ES 2055314T3 ES 90300840 T ES90300840 T ES 90300840T ES 90300840 T ES90300840 T ES 90300840T ES 2055314 T3 ES2055314 T3 ES 2055314T3
Authority
ES
Spain
Prior art keywords
csf
dysfunction
leukocytary
treatment
leukocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90300840T
Other languages
English (en)
Inventor
Eric M Bonnem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2055314T3 publication Critical patent/ES2055314T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Empleo de GM-CSF para la fabricación de un medicamento para empleo en un método de tratamiento de mamíferos con disfunción leucocitaria que está asociada con trauma físico, mediante la administración a dicho mamífero de una cantidad eficaz de GM-CSF para potenciar la función de dichos leucocitos.
ES90300840T 1989-01-30 1990-01-26 Tratamiento de disfuncion leucocitaria con gm-csf. Expired - Lifetime ES2055314T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30

Publications (1)

Publication Number Publication Date
ES2055314T3 true ES2055314T3 (es) 1994-08-16

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90300840T Expired - Lifetime ES2055314T3 (es) 1989-01-30 1990-01-26 Tratamiento de disfuncion leucocitaria con gm-csf.

Country Status (21)

Country Link
US (1) US5178855A (es)
EP (2) EP0382381B1 (es)
JP (1) JPH0651640B2 (es)
KR (1) KR0137361B1 (es)
AT (1) ATE89737T1 (es)
AU (1) AU633054B2 (es)
CA (1) CA2045605C (es)
DE (1) DE69001686T2 (es)
DK (1) DK0382381T3 (es)
ES (1) ES2055314T3 (es)
FI (1) FI913625A7 (es)
HK (1) HK46196A (es)
HU (1) HU207229B (es)
IE (1) IE64234B1 (es)
IL (1) IL93219A (es)
MY (1) MY105798A (es)
NZ (1) NZ243953A (es)
OA (1) OA09509A (es)
PT (1) PT92995B (es)
WO (1) WO1990008554A1 (es)
ZA (1) ZA90600B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
WO1994028919A1 (fr) * 1993-06-08 1994-12-22 Ajinomoto Co., Inc. Accelerateur de la proliferation des cellules hematopietiques
EP0791061A4 (en) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res ANIMALS WITH TARGETED INTERRUPTION
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2008079295A1 (en) * 2006-12-22 2008-07-03 Novadel Pharma Inc. Stable anti-nausea oral spray formulations and methods
US7841878B2 (en) * 2007-08-09 2010-11-30 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
WO1987002060A1 (en) * 1985-10-03 1987-04-09 Biogen N.V. Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
EP0246322B1 (en) * 1985-11-27 1992-08-26 Genetics Institute, Inc. Treatment of aids-type disease
EP0307402B1 (en) * 1986-05-06 1993-08-11 Genetics Institute, Inc. Production of m-csf
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
IL88344A (en) * 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages

Also Published As

Publication number Publication date
HU207229B (en) 1993-03-29
CA2045605C (en) 1997-02-11
MY105798A (en) 1995-01-30
EP0382381B1 (en) 1993-05-26
IE64234B1 (en) 1995-07-26
US5178855A (en) 1993-01-12
FI913625A0 (fi) 1991-07-30
AU5048890A (en) 1990-08-24
JPH0651640B2 (ja) 1994-07-06
CA2045605A1 (en) 1990-07-31
IL93219A (en) 1998-12-27
HK46196A (en) 1996-03-22
HUT57607A (en) 1991-12-30
JPH03504980A (ja) 1991-10-31
EP0382381A1 (en) 1990-08-16
ZA90600B (en) 1990-10-31
NZ243953A (en) 1997-06-24
OA09509A (en) 1992-11-15
IL93219A0 (en) 1990-11-05
IE900318L (en) 1990-07-30
DE69001686D1 (de) 1993-07-01
KR0137361B1 (ko) 1998-04-25
DE69001686T2 (de) 1993-09-02
FI913625A7 (fi) 1991-07-30
ATE89737T1 (de) 1993-06-15
AU633054B2 (en) 1993-01-21
EP0455726A1 (en) 1991-11-13
DK0382381T3 (da) 1993-07-12
PT92995A (pt) 1990-07-31
PT92995B (pt) 1995-12-29
KR910700069A (ko) 1991-03-13
WO1990008554A1 (en) 1990-08-09

Similar Documents

Publication Publication Date Title
ES2187659T3 (es) Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina.
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
NO944997D0 (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
MX9304110A (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento destinado a la profilaxis y a la terapia de enfermedades intestinales y cutaneas inflamatorias asi como de purpura.
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
DK261490D0 (da) New pharmaceutical compound
ES2173858T3 (es) Analogos de huperzina a.
ES2071833T3 (es) Agente para neutralizar la actividad procoagulante asociada a celulas tumorales.
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
ES2039489T3 (es) La utilizacion del compuesto alquilidenditio-bis-(substituidos)-fenoles sustituidos.
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
DK0535129T3 (da) Et antikoagulerende præparat
TW259710B (es)
ES2087915T3 (es) Agente terapeutico y procedimiento que inhibe la vascularizacion de tumores.
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
ES2117046T3 (es) Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
MX9206135A (es) Metodos
PH23658A (en) Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
JPS55113721A (en) Immunity regulator

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 382381

Country of ref document: ES